We present an overview of the current pharmacological treatment of urinary incontinence (UI) in women, according to the latest evidence available. After a brief description of the lower urinary tract receptors and mediators (detrusor, bladder neck, and urethra), the potential sites of pharmacological manipulation in the treatment of UI are discussed. Each class of drug used to treat UI has been evaluated, taking into account published rate of effectiveness, different doses, and way of administration. The prevalence of the most common adverse effects and overall compliance had also been pointed out, with cost evaluation after 1 month of treatment for each class of drug. Moreover, we describe those newer agents whose efficacy and safety need to be further investigated. We stress the importance of a better understanding of the causes and pathophysiology of UI to ensure newer and safer treatments for such a debilitating condition. Urinary incontinence has an observed prevalence of 25%, and this tends to increase with age.
T he term urinary incontinence (UI) refers to any type of involuntary urinary loss [International Continence Society (ICS)].
Urinary incontinence has an observed prevalence of 25%, and this tends to increase with age. 1 Normal functions of the female lower urinary tract are the storage of urine within the bladder and the timely release during micturition at appropriate intervals. Bladder and urethra act together as a functional unit during filling and voiding phases. Effective micturition and bladder control both require a well-functioning nervous system altogether with local regulatory factors. 2 Functional impairment at various levels may result in bladder control disorders, which can be roughly classified as disturbances of storage and disturbances of emptying. The various types of UIs in women, according to the ICS, are reported in Table 1 . 3 The annual incidence of UI in women ranges from 2% to 11%, with the highest incidence occurring during pregnancy. Rates of complete remission of UI range from 0% to 13%, with the highest remission rates after pregnancy. 4 The annual incidence of overactive bladder (OAB) ranges from 4% to 6%, with annual remission rates of OAB ranging from 2% to 3%. 5 Although conservative and behavioral therapy are important in the UI management in women, many patients may benefit from pharmacological therapy. The aim of this article was to provide an overview of the current therapeutical options in the pharmacological management of women with UI. New developments in the drug treatment of this condition are also pointed out. Drug therapy recommendations are based on the Oxford Classification System for Levels of Evidence. 6 The prices of the single drugs reported in this article and the weighted average cost for a monthly treatment are based on the US rates.
FUNCTIONAL ANATOMY AND NEUROPHYSIOLOGY OF THE LOWER URINARY TRACT
The female bladder and urethra have a somatic (pudendal) and an autonomic (sympathetic and parasympathetic) innervation (Fig. 1) . The pudendal nerve arises from the sacral nerve roots S2YS4 and supplies the external urethral sphincter. The parasympathetic nerves, which govern bladder contraction, are derived from the second, third, and fourth sacral segments of the spinal cord to the detrusor muscle. Sympathetic nerve supply of the bladder originates in the intermediolateral nuclei in the thoracolumbar region (T10-L2) of the spinal cord. Bladder storage and voidance involve a complex interplay of efferent and afferent signals in a way that parasympathetic, sympathetic, somatic, and sensory nerves can work synergically. 7 Contraction of the detrusor smooth muscle and relaxation of the outflow region result from the activation of parasympathetic neurons (S2YS4). The predominant effects of the sympathetic nerves in the lower urinary tract are inhibition of the parasympathetic pathways at spinal and ganglion levels and mediation of contraction of the bladder base and the urethra. During bladder filling, the outlet is closed, and the bladder smooth muscle is quiescent. When bladder volume increases to the micturition threshold, the activation of a micturition center in the dorsolateral pons (the pontine micturition center) elicits bladder contraction and the reciprocal relaxation of the urethra, leading to bladder emptying. During voiding, sacral parasympathetic pelvic nerves provide an excitatory input (cholinergic and purinergic) to the bladder and an inhibitory input (nitrergic) to the urethra (Fig. 2) . These peripheral networks are integrated by means of a feedback and feedforward regulation at spinal cord and brain levels. 8 There is increasing evidence showing that the urothelium has got specialized sensory and signaling properties, including expression of nicotinic, muscarinic, tachykinin, adrenergic, bradykinin, and transient receptor potential receptors, close physical association with the afferent nerves, and ability to release chemical molecules such as adenosine triphosphate (ATP), acetylcholine (ACh), and nitric oxide (NO). 8Y10 At present, the functional role of the muscarinic receptors in the urothelium has largely been indirectly investigated, that is, by studying the effects after urothelium removal or administration of pharmacological inhibitors. Thus, it seems that the muscarinic receptors in the urothelium also contribute to the overall bladder function regulation, but their specific roles have not been fully established. 11 The parasympathetic pelvic nerves stimulate the detrusor muscle via the muscarinic receptors M 2 and M 3 . These receptors are activated by ACh, whereas purinergic receptors (P2X1) are activated by ATP, inducing relaxation of the urethral smooth muscle, mediated by NO. Apparently, most muscarinic receptors in the bladder are found on the detrusor smooth muscle cells. Although the detrusor expresses far more M 2 (80%) than M 3 (20%) receptors, it seems that detrusor contraction under physiological conditions is largely (if not exclusively) mediated by the M 3 receptor. 12Y16 The > 1 -adrenoceptors (ARs) and the 3 A-AR subtypes (A 1 , A 2 , and A 3 ) have been investigated in the human detrusor. Human urothelium as well contains all 3 receptor subtypes. 17, 18 Real-time PCR and immunostaining revealed high concentrations of A 3 -AR throughout the urothelium, the detrusor nerve also release ACh, which produces a contraction of the external sphincter striated muscle by activating nicotinic cholinergic receptors. Parasympathetic postganglionic nerves also release ATP, which excites the bladder smooth muscle, and NO, which relaxes the urethral smooth muscle. Targets of the stress urinary incontinence (SUI) pharmacological treatment are the > and A-ARs, whereas in the OAB/urgency urinary incontinence (UUI) treatment, the site of interaction is the muscarinic receptor (Figs. 3 and 4) . 
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A thorough knowledge of the body distribution of muscarinic receptors is mandatory to start an appropriate pharmacological treatment (Table 2) . It is important to keep in mind that drugs acting on the muscarinic receptors are not specific for those present in the lower urinary tract. 2, 12, 13 This suggests that these drugs may cause systemic adverse effects (AEs) (Tables 2b and 2c ). Theoretically, drugs with selectivity for the bladder could be obtained if the receptor subtype(s) mediating bladder contraction and those producing the main AEs of antimuscarinic drugs were different. Unfortunately, this does not seem to be the case.
PHARMACOTHERAPY TREATMENT OF OAB AND UUI
Overactive bladder is the term used to describe the symptom complex of urgency, with or without urge incontinence, usually with frequency and nocturia. Overactive bladder symptoms are due to involuntary contractions of the detrusor muscle during the filling phase of the micturition cycle. These involuntary contractions are termed detrusor overactivity (DO) and are mediated by ACh-induced stimulation of the bladder muscarinic receptors. Urgency urinary incontinence is an involuntary loss of urine associated with urgency. Urodynamic testing shows an involuntary leakage from the urethra synchronous with the sensation of a sudden, compelling desire to void that is difficult to defer; during filling cystometry, involuntary detrusor muscle contractions can be detected. 31 Drug therapy continues to have an integral role in the management of women with OAB, and there are now a number of different agents available (Table 3) . Despite the clinical advantages of many of the pharmacological agents available, the occurrence of significant AEs and impaired compliance has limited their use. The availability of bladder selective drugs in the near future, once daily dosing and differing the routes of administration, may increase the compliance. However, in many cases, drugs may be considered as an adjunct to conservative therapy. An optimal treatment should be individualized, taking into consideration a number of factors, such as the patient's comorbidities and concomitant medications, together with the pharmacological profiles of different drugs.
DRUGS WITH MIXED ACTION Oxybutynin
Oxybutynin (Table 4a ) is a tertiary amine that undergoes an extensive first-pass metabolism to its active metabolite, N-desmethyl oxybutynin, which occurs in high concentrations and is thought to be responsible for a significant part of the action of the parent drug. T 1/2 = 2 hours. It has a mixed action consisting of 32, 33 : -Nonselective antimuscarinic = M1 and M3 99 M2 is its primary mechanism of action; -Direct smooth muscle relaxation (antispasmodic) = may involve blockage of Ca 2+ channels; -Local anesthetic properties = important only for intravescical infusion; -Antihistamine properties. 37 The use of oxybutynin gel elicits more local AEs compared to placebo (6.8% vs 2.8%). 38 However, the gel formulation may offer a better combination of reduced local and systemic AEs and is an alternative to oral preparations in those women who experienced intolerable antimuscarinic AEs (Tables 4b, 4c , and 4d).
Propiverine
Propiverine hydrochloride is a benzilic acid derivative compound. It is rapidly absorbed and has a high first-pass metabolism. Its mixed action involves antimuscarinic and Ca 2+ channel antagonism. 33 Propiverine has more recently been introduced as a long-acting once-daily preparation and may be useful in those women unable to tolerate other antimuscarinic drugs. Adverse effects are dry mouth (14%) and other AEs not well documented.
ANTIMUSCARINIC DRUGS
Recent large meta-analyses of the most widely used antimuscarinic drugs have clearly shown that these drugs provide a significant clinical benefit (Table 5) . 31, 39, 40 However, none of the commonly used antimuscarinic drugs are an ideal first-line treatment for OAB/DO patients. There is no consistent evidence that 1 antimuscarinic drug is superior to an alternative antimuscarinic drug for the cure or the improvement of UUI. An optimal treatment should be individualized, taking into consideration any associate conditions and concomitant medications and the pharmacological profiles of different drugs. Recommendations on the use of these drugs 41 are shown in Table 6 . Contraindications are uncontrolled narrow-angle glaucoma, significant cardiac arrhythmias, urinary retention, gastric retention, myasthenia gravis, severe renal and hepatic diseases, acquired cognitive impairment and dementia (Alzheimer disease), and concomitant treatment with acetylcholinesterase (AChE) inhibitors.
The treatment of OAB/DO in the elderly deserves specific considerations. Overactive bladder is more common in the elderly, where it causes a detrimental effect on the QoL. It has been established that 30.9% of women older than 65 years have this condition. Studies have shown that 40% of patients with Alzheimer dementia experience OAB. 42 Many of these patients are taking AChE inhibitors like donepezil, galantamine, and rivastigmine. AChE inhibitors fall under the parasympathomimetic group of medications, whose effects are antagonized by antimuscarinic drugs. 43 Overactive bladder treatment in patients taking AChE inhibitors remains difficult. A pilot study 44 found improvement in OAB symptoms with the use of propiverine hydrochloride in patients taking Donepezil for cognitive impairment, without changes in cognition. More research is required in this field.
Solifenacin
This compound is a bladder-selective antimuscarinic 33 agent that has greater specificity for the M 3 receptors over the M 2 receptors and has much higher potency against M 3 receptors in smooth muscle than it does against M 3 receptors in salivary glands (Table 7a ). It shows a long half-life. Its long-term efficacy has been assessed in a 12-month follow-up study of 1637 patients. 45 There was a significantly greater reduction in urgency episodes in the solifenacin arm compared to the placebo arm (P G 0.001) and the difference in the median length of warning time was 31.5 seconds in the solifenacin group compared to the 12.0 seconds of the placebo group (P = 0.032). 38 When compared with oxybutynin, solifenacin showed a better efficacy with lower AEs. 42 There were statistically significant differences in QoL, patient reported cure, all favoring solifenacin. The recommended starting dose of 5 mg once daily has been compared to 10 mg, showing lower rate of frequency and urgency. The dry mouth was significantly lower with solifenacin when compared to tolterodine. Solifenacin 5 mg once daily is the usual starting dose, which could be increased to (Tables 7b and 7c ).
Tolterodine
Tolterodine (Table 8a) is a tertiary amine which is rapidly absorbed. Its low lipid solubility implies a poor capacity to cross the blood-brain barrier. 33 T 1/2 = 2Y3 hours. This drug is metabolized into the liver to its 5-hydroxymethyl derivative, which is an active metabolite having a similar pharmacokinetic profile and is thought to significantly contribute to the therapeutic effect. 46 It is a competitive muscarinic receptor antagonist with relative functional selectivity for bladder receptors, 47 and, although it shows no specificity for receptor subtypes, it does seem to target the bladder over the salivary glands. 48 No differences in QoL and improvement of leakage episodes are reported when comparing tolterodine with oxybutynin in 8 trials. Where the prescribing choice is between oral IR oxybutynin and tolterodine, tolterodine might be preferred for reduced risk of dry mouth. The starting dose is 2 mg twice daily. The effects of 1-, 2-, and 4-mg doses were similar for leakage episodes and micturitions in the 24 hours, with a greater risk of dry mouth with the 2-and 4-mg doses at 2 to 12 weeks (Tables 8b and 8c) . 36 
Trospium
Trospium chloride is a quaternary ammonium compound (this means that it crosses the blood-brain barrier to a limited extent and hence would seem to have few cognitive effects) that shows low biological availability (Table 9a) . 40 T 1/2 = 20 hours. Its mechanism of action is nonselective for muscarinic receptor subtypes: it blocks detrusor smooth muscle receptors as well as receptors in the ganglia. 33 The efficacy and tolerability of once daily trospium chloride has also been confirmed in a further large study of 564 patients with OAB 49 ; this drug seems to have a meaningful impact on QoL. 50 However, in 4 comparative studies, A Consider using transdermal oxybutynin if oral antimuscarinic agents cannot be tolerated due to dry mouth. B Offer and encourage early review (of efficacy and AEs) of patients on antimuscarinic medication for urge urinary incontinence (G30 d) A When prescribing antimuscarinic drugs to elderly patients, be aware of the risk of cognitive AEs, especially in those receiving cholinesterase inhibitors.
C Avoid using oxybutynin IR in patients who are at risk of cognitive dysfunction. A Consider use of trospium chloride in patients known to have cognitive dysfunction. B Use antimuscarinic drugs with caution in patients with cognitive dysfunction. B Do an objective assessment of mental function before treating patients whose cognitive function may be at risk. C Check mental function in patients on antimuscarinic medication if they are at risk of cognitive dysfunction. C trospium seems not to be better than oxybutynin in terms of efficacy. 51Y55 It is available in oral IR and XR formulations. A comparison that might benefit from further research is the evaluation of trospium versus oxybutynin or tolterodine in terms of safety. Because trospium is a quaternary amine and oxybutynin and tolterodine are tertiary amines, we could expect less neurological AEs in patients with cognitive impairment. Patients already on multiple medications could benefit from this compound because of its low metabolism by liver enzymes (Tables 9b and 9c ).
Darifenacin
Darifenacin is a tertiary amine with a long half-life. It has moderate lipophilicity and is a highly selective M 3 receptor antagonist which has been found to have a 5-fold higher affinity for the human M 3 receptor, compared to the M 1 receptor (Table 10a) . 56 Its efficacy has been investigated in a multicenter, double-blind, placebo-controlled, parallel-group study which enrolled 561 patients with symptoms of OAB. 57 It is available for oral intake. Significant decreases in frequency and severity of urgency, micturition frequency, and number of incontinence episodes were also observed, along with an increase in bladder capacity. Darifenacin was well tolerated. The incidence of CNS and cardiovascular adverse events were comparable to placebo (Tables 10b and 10c) . 58 
Fesoterodine
Fesoterodine is a new and novel derivative of 3,3-diphenylpropyl-amine. Fesoterodine is a competitive muscarinic receptor antagonist (Table 11a) . 59 After oral administration, the compound is rapidly hydrolyzed in its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), which is responsible for the antimuscarinic activity of the drug and has the same activity as tolterodine. T 1/2 = 7Y8 hours [approved by the Food and Drug Administration (FDA) for the treatment of OAB]. The lipophilicity and permeability across biological membranes has been shown to be considerably lower for 5-HMT as compared to tolterodine, and 5-HMT formation from fesoterodine by the ubiquitous nonspecific esterases is more consistent. 60 The efficacy of fesoterodine versus ER tolterodine has been evaluated in 3 trials, later included in a recent Cochrane review 36 : fesoterodine was superior to tolterodine in terms of reduction of urgency episodes, frequency, and leakage episodes. Patients taking fesoterodine had higher risk of withdrawal due to adverse events. Fesoterodine, 8 mg daily, is more effective than tolterodine ER, 4 mg daily, for the cure and the improvement of UUI (Tables 11b, 11c , and 11d). 41 
Atropine Sulfate
Drug Name: Levsin
Derived from the plant Atropa belladonna, this is the prototype of all antimuscarinic agents. 33 It is rarely used for the treatment of OAB/DO because of its systemic AEs, which preclude its use as an oral treatment. However, in patients with neurogenic DO (NDO), intravesical atropine may be effective for increasing bladder capacity without causing any systemic AEs, as shown in open pilot trials.
60Y64 Sublingual form may have fewer AEs, whereas intravescical form may be effective without AEs. 33 
Propantheline Bromide
Drug Name: Pro-Banthine It is a quaternary ammonium compound with a nonselective antimuscarinic action. It has a low (5%Y10%) and individually varying biological availability. After metabolization has occurred, 31 its metabolites remain inactive. 65 The effect of propantheline on OAB/DO has not been well documented in controlled trials satisfying current standards; it can be considered effective, and may, in individually titrated doses, be clinically useful. 7 
>-ADRENERGIC ANTAGONISTS
Their mechanism of action is urethral sphincter tone increase. So far, there are no controlled clinical trials showing that >-adrenergic antagonist is an effective alternative in the treatment of OAB/DO. 7 A randomized controlled trial (RCT), comprising 364 women with OAB, revealed no effect of tamsulosin versus placebo. 66 On the other hand, voiding symptoms in women with functional outflow obstruction, or lower urinary tract symptoms, were successfully treated with an > 1 -AR antagonist. 67, 68 In women, these drugs may produce stress incontinence due to their >-lytic mechanism. 69 Tamsulosin demonstrated effectiveness in female patients with voiding dysfunction, independently of the obstruction grade. A recent study on >1-AR antagonists offers an initial treatment option for women affected by nonneurogenic voiding dysfunction. 70 
A-AR AGONISTS
A-Adrenoceptors have been previously treated. The exact mechanism of signaling pathway involving this class of drugs at the urothelium level has to be clarified. Several studies conducted in vitro and in vivo have shown a myorelaxant effect of A-AR agonists; however, role of the A 3 -AR agonists remains to be elucidated. 7 A number of A 3 -AR selective agonists, including solabegron (phase II), are currently being evaluated as potential treatments for OAB in humans.
Mirabegron
In June 28, 2012, the FDA approved Myrbetriq (mirabegron, hitherto known as YM-178) to treat adults with OAB/UUI. Myrbetriq relaxes the detrusor smooth muscle during filling by activation of A 3 -ARs, increasing bladder capacity (Table 12a) . 71, 72 Its safety and efficacy were demonstrated in 3 double-blind, placebo-controlled, multicenter clinical trials (Table 12b) . 70 Recommended starting dose is 25 mg once daily; 25 mg is effective within 8 weeks. 72 In a study by Nitti et al, 73 1329 patients were randomized to receive placebo, mirabegron 50 mg, or 100 mg once daily for 12 weeks. At the final visit, mirabegron 50 and 100 mg showed statistically significant improvements in efficacy and mean volume voided/micturition compared with placebo.
Chapple et al 74 compared the long-term administration safety and efficacy of mirabegron 50 and 100 mg and tolterodine 75 have demonstrated a significant reduction of incontinence episodes and micturition frequency.
In patients with severe renal impairment or with moderate hepatic dysfunction, maximum dose is 25 mg once daily. In patients with end-stage renal disease or with severe hepatic impairment, the use of this drug is not recommended. In pregnancy, it can be used only if the benefit to the mother outweighs the potential risk of the fetus. Myrbetriq is not recommended in breast-feeding mothers because it is excreted in human milk.
In a proof-of-concept study of mirabegron 100 and 150 mg twice daily, 76 AEs were reported by 45.2% of patients, and the incidence was similar among those treated with placebo (43.2%) and mirabegron (43.8%Y47.9%). The most commonly reported AEs were treatment-related gastrointestinal disorders, including constipation, dry mouth, dyspepsia, and nausea. There was no patient-reported acute retention.
In a study reported by Khullar et al, 77 the incidence of AEs was similar across the placebo, mirabegron 50 and 100 mg groups (50.1%, 51.6%, and 46.9%, respectively; Table 12c ). Comparative studies with tolterodine, 78, 79 shown in Table 12d , were also carried out.
NEUROTOXINS Botulinum
Botulinum toxin (BONT onabotulinumtoxinA) is a neurotoxin produced by Clostridium botulinum (Table 13) . Uninhibited urinary bladder contractions in people with some neurological conditions can lead to the inability to store urine. The treatment consists of Botox injection into the bladder that induces detrusor relaxation, an increase in its storage capacity, and a decrease in UI. 80 In 2011 the FDA approved Botox injections to treat UI in people with neurologic conditions, such as spinal cord injury and multiple sclerosis, experiencing OAB. Observational studies are currently in progress with the aim to assess Botox efficacy and safety in neurogenic treatment in patients affected by Parkinson disease, and to assess risks and benefits of its long-term use for OAB/UUI treatment. 81Y83 The recommended dose is 200 U of BOTOX per treatment, and should not be exceeded.
Adverse effects are urinary tract infections and retention.
Vanilloid Receptors Agonist
These receptors are present on the afferent sensory neurons innervating detrusor and urethra. The rationale for intravesical vanilloid agonist application in patients with DO was offered by the demonstration that capsaicin, after bladder C-fiber desensitization, suppresses involuntary detrusor contractions dependent upon a sacral micturition reflex. 84 The C-fiber micturition reflex is usually inactive but it was shown that it is enhanced in patients with chronic spinal-cord lesions above sacral segments and in those with chronic bladder outlet obstruction. 85 
Capsaicin
Capsaicin has been used for intravescical instillation in patients affected by NDO. 7, 33 Capsaicin suppresses involuntary detrusor contractions after chronic spinal cord lesions above 
Head to Head
Mirabegron vs tolterodine:
The incidence and severity of treatment-emergent serious AEs (primary outcome parameters) were similar across the mirabegron 50 mg (59.7%), mirabegron 100 mg (61.3%), and tolterodine sustained-release 4 mg (62.6%) groups.
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During 12 mo of treatment, 2.8% of mirabegron 50 mg once daily recipients reported dry mouth compared with 8.6% with tolterodine ER 4 mg once daily recipients. 77 On the basis of descriptive analyses from a 12-mo trial, once-daily mirabegron 50 mg and tolterodine ER 4 mg were both efficacious in reducing urinary symptoms and improving health-related QoL. OnabotulinumtoxinA Total dose 200 U, as 1 mL (~6.7 U) injections across 30 sites into the detrusor sacral segments. Intravesical capsaicin for NDO was studied in 6 noncontrolled and 1 controlled clinical trials. After capsaicin has been dissolved in 30% alcohol and 100 to 125 mL of sterile water, 1 to 2 mM are instilled into the bladder and left in contact with the mucosa for 30 minutes. The pungency of alcoholic capsaicin solutions has prevented the widespread use of this compound. 7 In the single randomized study comparing the capsaicin solution against the use of 30% ethanol, a significant reduction of urge incontinence was found. The pungency of alcoholic capsaicin solutions has prevented the widespread use of this compound.
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Resiniferatoxin
This compound, derived from the cactus-like plant Euphorbia, is 1000 times more potent, but much less pungent, than capsaicin. 7, 33 Different resiniferatoxin (RTX) concentrations, 10 nM, 50 nM, 100 nM, and 10 KM, were tested. Resiniferatoxin brought a rapid improvement or disappearance of UI in up to 80% of the selected patients and a 30% decrease in their daily urinary frequency. 86 Furthermore, RTX also increased the volume to first detrusor contraction and the maximal cystometric capacity. In general, in patients receiving 50-to 100-nM RTX, the effect was long-lasting, with a duration of more than 6 months being reported. In patients treated with 10-KM doses, transient urinary retention may occur. 87 Currently, new experimental tests are in progress to test its safety and efficacy.
PHARMACOLOGICAL TREATMENT OF SUI
Stress urinary incontinence is defined as an involuntary loss of urine on effort or physical exertion (or on sneezing or coughing) 7 associated with increased intra-abdominal pressure (stress test), in the absence of a detrusor contraction. 31 Although various agents such as > 1 -AR agonists, estrogens, and tricyclic antidepressants have all been used anecdotally in the past for the treatment of stress incontinence, duloxetine is the first drug to be specifically developed and licensed for this indication. 38 Drugs used for SUI are shown in Table 14 .
ANTIDEPRESSANT Selective Norepinephrine and Serotonin Reuptake Inhibitors
Duloxetine Duloxetine (Cymbalta) is a potent and balanced serotonin (5-hydroxytryptamine) and noradrenaline reuptake inhibitor (Table 15a) . 88 T 1/2 = 12 hours. Its elimination is mainly through hepatic metabolism. Its ability to stimulate the pudendal motoneurons (target: Onuf's nucleus, in the sacral spinal cord) and to increase striated urethral sphincter contractility is thought to be the basis for its efficacy in women with SUI. Dmochowski et al 89 randomized 683 women, 22 to 84 years old, to duloxetine or placebo. There was a significant decrease in incontinence episode frequency with duloxetine compared with placebo (50% vs 27%, P, 0.001), with comparably significant improvements in QoL (11.0 vs 6.8, P, 0.001). Duloxetine has been approved for the treatment of SUI in Europe, although the FDA has not approved it for this purpose. Liver toxicity and suicidal events represent a great concern. However, an observation study from Michel et al 90 has shown that women with SUI treated with duloxetine doses lower than recommended reported a low incidence of AEs and suicide attempts were not reported. Cymbalta was first used to treat major depressive disorder and generalized anxiety disorder. Subsequently, FDA approved Cymbalta to treat chronic musculoskeletal pain, including discomfort from osteoarthritis, chronic lower back pain, and fibromyalgia, but failed the US approval for SUI amid concerns over liver toxicity and suicidal events, whereas it was approved for this indication in Europe, where it is recommended as an add-on medication instead of surgery. The efficacy and safety of duloxetine (20, 40 , and 80 mg; Table 15b ) for treatment of SUI has been evaluated in a study by Norton et al, 91 that involved 48 centers in the United States, including 553 women with SUI, and Deepak et al. 92 Duloxetine was associated with a significant dose-dependent decrease in incontinence episode frequency; reductions were 41% for placebo and 54%, 59%, and 64% for the 20-, 40-, and 80-mg groups, respectively. Discontinuation rates were also dose dependent; 5% for placebo and 9%, 12%, and 15% of 20, 40, and 80 mg, respectively. 93 Nausea is the most frequently reported AE. There was a significant decrease in incontinence episode frequency and improvement in QoL in those women taking duloxetine 40 mg o.d. when compared to placebo. 38 Escalating the dose upon initiation of the treatment has been shown to reduce the frequency of AEs. 94 From the whole group, 20% of patients cancelled surgery after 2 months on duloxetine. The main adverse event was nausea, ranging from 23% to 25%. In these 6 trials, the percentage of withdrawals due to AEs resulted to be 17% in the drug group compared to 4% in the placebo arm. 7 The most frequent AEs are reported in Table 15c . Dysphoric mood, irritability, agitation, paresthesias, anxiety, confusion, emotional lability, hypomania, and tinnitus are generally self-limiting; some have been reported to be severe. In a systematic review performed to assess duloxetine safety and tolerability for SUI, no case of suicide has been reported. 95 An observational study on the same subject including 3233 women did not report any case of suicide during the treatment. 90 
Tricyclic Antidepressants
Imipramine
Imipramine is a tertiary amine of the tricyclic antidepressant group; its mechanism of action is norepinephrine and serotonin reuptake inhibition and it is thought to improve contraction of the urethral smooth muscle (Table 16a) . 2 This drug is derived from chlorpromazine, so it has the same blocking effects on muscarinic (M 1 ), adrenergic, and histaminergic receptors, that cause the relative AEs. Several researchers have found a significant effect in the treatment of patients with DO 96 although others report little effect. 97 It may be used to treat SUI or mixed incontinence. In the light of this evidence and the serious AEs associated with tricyclic antidepressants, their role in DO remains of uncertain benefit, although they are often useful in patients complaining of nocturia or bladder pain. 38 It has been known for a long time that imipramine can have favorable effects in the treatment of nocturnal enuresis in children, with a success rate of 10% to 70% in controlled trials. 98, 99 Adverse effects are shown in Table 16b .
>-Adrenergic Agonists
Several drugs with agonistic effects on >-ARs have been used in the treatment of SUI. However, ephedrine and norephedrine (phenylpropanolamine) seem to have been the most widely used. 100 There was weak evidence to suggest that use of an adrenergic agonist was better than placebo treatment. 7 The limited evidence suggested that such drugs were better than placebo in reducing the number of pad changes and incontinence episodes, and in improving subjective symptoms. Phenylpropanolamine, clonidine (Catapres), ephedrine, and pseudoephedrine belong to this category. >-Adrenergic agonists are not selective for bladder receptors: they are not recommended in people with glaucoma, diabetes, hyperthyroidism, heart disease, or high blood pressure. The selective >1-AR agonist midodrine is approved for SUI in Portugal. 101 
Phenylpropanolamine
Phenylpropanolamine is a nonselective >-ARs agonist which is capable to bind A-adrenergic receptors and enhances release of NE by presynaptic neurons. 33 This drug can be effective in patients with mid-SUI, but it is no longer dispensed in the United States because of the AEs reported later. Phenylpropanolamine is approved in Finland for the treatment of SUI. 101 Adverse effects are as follows: cardiac arrhythmias, hypertension, insomnia, headache, tremor, anxiety, and stroke (in women taking appetite suppressants).
A-AR Antagonists
A-Adrenoceptor antagonists inhibit urethral A-ARs and this may increase noradrenaline action on the urethral >-ARs. 
A-AR Agonists
A-Adrenoceptor stimulation is generally conceded to decrease urethral pressure, 104 but A 2 -AR agonists have been reported to have a different action on fast-and slow-contracting skeletal muscle contractility. 105 Clenbuterol, a selective A 2 -AR agonist, is approved for the treatment of SUI in Japan. 106 
PHARMACOTHERAPY OF MIXED INCONTINENCE
The optimum treatment of mixed urinary incontinence (MUI) may often require multiple treatment modalities. One should treat most bothersome symptoms first. 5 Behavioral therapy and lifestyle modification, such as moderate weight loss and caffeine reduction, should be considered first-line options for all women with MUI. Pharmacological treatment of the urge component with antimuscarinics is effective. The addition of pelvic floor muscle therapy may have an additional benefic effect. Often a surgical procedure for the incontinence stress component significantly improves both symptoms. Anti-incontinence surgery may have a positive impact on both the stress and the urge components of MUI; however, it seems that women with MUI may have lower cure rates compared to women with pure SUI.
If the initial pharmacological approach fails, consider the use of botulinum toxin or neuromodulation.
HORMONAL TREATMENT OF UI Desmopressin
Desmopressin (Table 17) is a synthetic analog of vasopressin (antidiuretic hormone). Desmopressin (DDVAP) was found to be well tolerated and resulted in a significant improvement compared to placebo in reducing nocturnal voids/UI and increasing the hours of undisturbed sleep. 5 Studies are in progress to test if desmopressin improves nocturnal enuresis in patients after radical cystectomy with bladder reconstruction, and the impact on sleep and daytime functioning. The drug is available in a range of formulations: intranasal solution (spray), injectable solution, tablets and, most recently, an oral lyophilisate. Intranasal and oral formulations are generally well tolerated, and AEs are usually minor. Usual adult dose, in oral formulations, is 0.2 to 0.6 mg every day at hours of sleep. One of the most feared AEs (although rare) is hyponatremia. However, precautions in prescribing desmopressin for this condition and compliance monitoring will help prevent this complication. Adverse effects are as follows: dizziness, headache, mood change, vomiting, weakness, loss of appetite, feeling restless or irritable, confusion, and hallucinations.
Estrogens
Bladder, urethra, and pelvic floor estrogen sensibility plays an important role in the continence mechanism (Table 18 ). 7 Many studies have shown that oral estrogen replacement, alone or combined with a progesterone, has poor results in terms of continence. In the women health initiative study, HRT was found to increase the incidence of all types of UI at 1 year in those women continent at baseline. The most recent metaanalysis on the effects of estrogen therapy on the lower urinary tract showed that overall systemic administration resulted in worse incontinence than that of placebo. 107 The use of local estrogen therapy may improve incontinence (RR, 0.74; 95% CI, 0.64Y0.86), reducing frequency and urgency. 107 The subjective improvement in symptoms may simply represent local estrogenic effects reversing urogenital atrophy rather than a direct effect on bladder function. Reliable data are too scant to suggest the dose, type of estrogens, and route of administration.
PRACTICAL SUGGESTIONS
Conclusively, considering the similar pharmacological profile of the different drugs used for the UUI treatment, we suggest starting with instant release form of antimuscarinic drugs. Darifenacin, solifenacin and tolterodine seem to offer a good bioavailability and efficacy with acceptable AEs. Assessment of efficacy and AEs of the treatment within 30 days from the beginning of the therapy is mandatory. Specific caution must be taken when using instant release oxybutynin in patient with cognitive dysfunction. Consider use of transdermal oxybutynin in those patients experiencing dry mouth. Regarding the use of duloxetine for SUI, the FDA has not given approval for this purpose. However, use of duloxetine in the daily practice with doses lower then recommended has shown a low incidence of AEs with a significant decrease in incontinence episode frequency and improvement in QoL.
SUGGESTIONS FOR FURTHER RESEARCH
The following classes of drugs need to be investigated to find out if they could be helpful in the treatment of any form of incontinence:
-Solabegron (A3-adrenergic agonist): phase II; -Cizolirtine citrate (antimuscarinic agent): phase II; -Tramadol (K-receptor agonist): off-label; -Gabapentin: off-label; -Aprepitant (neurokinin-1 receptor antagonist): off-label 
